Kennyoscar
2021-12-15
Owo
BeiGene Shares Dive in China as Third Listing Begins
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":607260666,"tweetId":"607260666","gmtCreate":1639547784327,"gmtModify":1639547784821,"author":{"id":3575882730419858,"idStr":"3575882730419858","authorId":3575882730419858,"authorIdStr":"3575882730419858","name":"Kennyoscar","avatar":"https://static.tigerbbs.com/7ae5bbd70eee00b69de3be27b8862938","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":9,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":47,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Owo</p></body></html>","htmlText":"<html><head></head><body><p>Owo</p></body></html>","text":"Owo","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/607260666","repostId":1181903786,"repostType":4,"repost":{"id":"1181903786","kind":"news","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1639547541,"share":"https://www.laohu8.com/m/news/1181903786?lang=&edition=full","pubTime":"2021-12-15 13:52","market":"hk","language":"en","title":"BeiGene Shares Dive in China as Third Listing Begins","url":"https://stock-news.laohu8.com/highlight/detail?id=1181903786","media":"Dow Jones","summary":"Chinese biopharmaceutical company BeiGene Ltd. stumbled in its trading debut in China, tracking the ","content":"<p>Chinese biopharmaceutical company BeiGene Ltd. stumbled in its trading debut in China, tracking the recent slide in its overseas shares as it became the first company to be listed in the U.S., Hong Kong and the Shanghai STAR market.</p>\n<p>BeiGene shares fell 20% below its initial public offering price before recovering some ground. The stock was last down 13% at 168.02 yuan (US$26.39) at mid-day on Wednesday.</p>\n<p>Beijing-based BeiGene, which specializes in cancer treatment, has had American Depository Shares listed on the Nasdaq since 2016, and floated shares in Hong Kong in 2018. The company's Hong Kong shares were last down 5.8% at HK$165.20 in Wednesday mid-day trade.</p>\n<p>BeiGene raised gross proceeds of about US$3.5 billion in its China offering, the biggest of the year on Shanghai's tech-heavy STAR Market, issuing 115.1 million shares at CNY192.60 each. The company plans to using the funding in part to develop its suite of cancer therapy drugs.</p>\n<p>Investment bank Jefferies recently rated the company's Hong Kong shares a buy with a HK$210.80 price target. It highlighted a cancer drug approved for clinical trials in China, describing its safety as superior to that of similar drugs.</p>\n<p>Nomura last week initiated coverage of BeiGene with a neutral rating and a target price of HK$214.05 on Hong Kong shares, noting the company's global reach, nine approved drugs approved in the U.S. and China, and collaborations with global pharma leaders including Novartis AG and Amgen Inc.</p>\n<p>Nomura expects the company to register sales of US$1.63 billion by 2023 and turn profitable by 2026.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeiGene Shares Dive in China as Third Listing Begins</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeiGene Shares Dive in China as Third Listing Begins\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-15 13:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Chinese biopharmaceutical company BeiGene Ltd. stumbled in its trading debut in China, tracking the recent slide in its overseas shares as it became the first company to be listed in the U.S., Hong Kong and the Shanghai STAR market.</p>\n<p>BeiGene shares fell 20% below its initial public offering price before recovering some ground. The stock was last down 13% at 168.02 yuan (US$26.39) at mid-day on Wednesday.</p>\n<p>Beijing-based BeiGene, which specializes in cancer treatment, has had American Depository Shares listed on the Nasdaq since 2016, and floated shares in Hong Kong in 2018. The company's Hong Kong shares were last down 5.8% at HK$165.20 in Wednesday mid-day trade.</p>\n<p>BeiGene raised gross proceeds of about US$3.5 billion in its China offering, the biggest of the year on Shanghai's tech-heavy STAR Market, issuing 115.1 million shares at CNY192.60 each. The company plans to using the funding in part to develop its suite of cancer therapy drugs.</p>\n<p>Investment bank Jefferies recently rated the company's Hong Kong shares a buy with a HK$210.80 price target. It highlighted a cancer drug approved for clinical trials in China, describing its safety as superior to that of similar drugs.</p>\n<p>Nomura last week initiated coverage of BeiGene with a neutral rating and a target price of HK$214.05 on Hong Kong shares, noting the company's global reach, nine approved drugs approved in the U.S. and China, and collaborations with global pharma leaders including Novartis AG and Amgen Inc.</p>\n<p>Nomura expects the company to register sales of US$1.63 billion by 2023 and turn profitable by 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"688235":"百济神州","BGNE":"百济神州","06160":"百济神州"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1181903786","content_text":"Chinese biopharmaceutical company BeiGene Ltd. stumbled in its trading debut in China, tracking the recent slide in its overseas shares as it became the first company to be listed in the U.S., Hong Kong and the Shanghai STAR market.\nBeiGene shares fell 20% below its initial public offering price before recovering some ground. The stock was last down 13% at 168.02 yuan (US$26.39) at mid-day on Wednesday.\nBeijing-based BeiGene, which specializes in cancer treatment, has had American Depository Shares listed on the Nasdaq since 2016, and floated shares in Hong Kong in 2018. The company's Hong Kong shares were last down 5.8% at HK$165.20 in Wednesday mid-day trade.\nBeiGene raised gross proceeds of about US$3.5 billion in its China offering, the biggest of the year on Shanghai's tech-heavy STAR Market, issuing 115.1 million shares at CNY192.60 each. The company plans to using the funding in part to develop its suite of cancer therapy drugs.\nInvestment bank Jefferies recently rated the company's Hong Kong shares a buy with a HK$210.80 price target. It highlighted a cancer drug approved for clinical trials in China, describing its safety as superior to that of similar drugs.\nNomura last week initiated coverage of BeiGene with a neutral rating and a target price of HK$214.05 on Hong Kong shares, noting the company's global reach, nine approved drugs approved in the U.S. and China, and collaborations with global pharma leaders including Novartis AG and Amgen Inc.\nNomura expects the company to register sales of US$1.63 billion by 2023 and turn profitable by 2026.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1052,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/607260666"}
精彩评论